JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

14.83 4.66

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.17

Max

14.92

Galvenie mērījumi

By Trading Economics

Ienākumi

3.9M

4.5M

Pārdošana

5.9M

24M

EPS

0.35

Dividenžu ienesīgums

0.48

Peļņas marža

18.669

Darbinieki

212

EBITDA

4.9M

7.2M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+14.37% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.36%

Nākamie ieņēmumi

2026. g. 13. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

44M

295M

Iepriekšējā atvēršanas cena

10.17

Iepriekšējā slēgšanas cena

14.83

Ziņu noskaņojums

By Acuity

24%

76%

65 / 347 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. maijs 21:36 UTC

Iegādes, apvienošanās, pārņemšana

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

2026. g. 1. maijs 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

2026. g. 1. maijs 18:37 UTC

Galvenie tirgus virzītāji

Senseonic Shares Slide on Underwritten Offering Price

2026. g. 1. maijs 16:46 UTC

Galvenie tirgus virzītāji

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2026. g. 1. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 1. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 1. maijs 20:42 UTC

Peļņas

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

2026. g. 1. maijs 19:33 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 1. maijs 19:33 UTC

Tirgus saruna

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

2026. g. 1. maijs 19:18 UTC

Tirgus saruna
Galvenie ziņu notikumi

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

2026. g. 1. maijs 19:13 UTC

Tirgus saruna

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

2026. g. 1. maijs 18:36 UTC

Peļņas

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

2026. g. 1. maijs 18:35 UTC

Peļņas

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

2026. g. 1. maijs 18:28 UTC

Peļņas

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

2026. g. 1. maijs 18:27 UTC

Tirgus saruna

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

2026. g. 1. maijs 18:14 UTC

Iegādes, apvienošanās, pārņemšana

Barclays Completes Acquisition of Best Egg

2026. g. 1. maijs 18:04 UTC

Peļņas

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

2026. g. 1. maijs 17:43 UTC

Tirgus saruna

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

2026. g. 1. maijs 17:37 UTC

Tirgus saruna

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

2026. g. 1. maijs 17:30 UTC

Tirgus saruna
Peļņas

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

2026. g. 1. maijs 17:28 UTC

Tirgus saruna
Peļņas

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

2026. g. 1. maijs 17:21 UTC

Tirgus saruna
Peļņas

Apple Seen Absorbing Higher Memory Costs -- Market Talk

2026. g. 1. maijs 17:19 UTC

Tirgus saruna
Galvenie ziņu notikumi

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

2026. g. 1. maijs 16:38 UTC

Tirgus saruna

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

2026. g. 1. maijs 16:23 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

2026. g. 1. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 1. maijs 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 1. maijs 16:15 UTC

Peļņas

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

2026. g. 1. maijs 16:11 UTC

Tirgus saruna

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

2026. g. 1. maijs 16:04 UTC

Peļņas

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

14.37% augšup

Prognoze 12 mēnešiem

Vidējais 16 USD  14.37%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

1

Turēt

0

Pārdot

Noskaņojums

By Acuity

65 / 347 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat